º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Enterprise

Welsh Government life sciences investment fund closing after £27m in write-offs

The Wales Life Sciences Investment Fund was launched in 2013 and invested £50m in new firms.

The fund's biggest write-off came through the liquidation of Rutherford Health.(Image: North News & Pictures Ltd)

A Welsh Government flagship equity fund to support the growth of life sciences firms is being wound up after £27m of its investments were written off, with its performance being labelled a “national embarrassment” by the Tories.

The £50m Wales Life Sciences Investment Fund (SWLSIF), championed by Port Talbot-born life sciences investor and serial entrepreneur Sir Chris Evans and then Economy Minister Edwina Hart, went live in 2013 .

In a procurement process overseen by Finance Wales (now the Development Bank of Wales), the contract to manage the fund was awarded to a company called Arthurian Life Sciences which was chaired Sir Chris. Although there was no requirement for the fund manager to match fund the £50m, the 11 investments into nine firms made by the WSLIF leveraged a further £200m of private sector investment which help to bring a number of life sciences firms to Wales, including ReNeuron.

Like ReNeuron some of the firms investing in by the fund, like many in the º£½ÇÊÓÆµ life sciences sector, were pre-revenue and in need of significant further funding to get through clinical trials and towards commercialisation.

The now fully invested fund, which comes under the Development Bank of Wales - which is wholly-owned by the Welsh Government- has been managed since 2017 by Arix Capital Management following the acquisition of Arthurian by Arix Bioscience.

The biggest hit to the fund came with the collapse last year of proton beam cancer treating centre business Rutherford Health in which it has invested £10m in equity as part of a £100m investment round in 2015.

There was one notable success for the fund with its equity investment into Merthyr-based drug trail specialist Simbec Orion. Having invested more than £8.75m into Simbec, its subsequent acquisition through a private equity financed management buyout in 2019, generated a £20m capital return to the Welsh Government - after the proceeds from the exit where passed back to it by Development Bank of Wales. The fund created and safeguarded more than 300 jobs in Wales.

The Development Bank of Wales in its latest audited accounts for its 2022-23 financial year shows an accumulated write-off position of £27.1m for the fund.